Chronic myelogenous leukemia (CML): How to tell if it is getting worse

Chronic myelogenous leukemia (CML) is one of those conditions that can feel oddly “quiet” for a long timeuntil something changes.
The tricky part is that those changes might show up as symptoms you can feel, numbers on a lab report, or a pattern your oncologist notices
over several visits. And because many CML symptoms overlap with everyday life (fatigue, anyone?), it’s normal to wonder:
Is my CML getting worse… or am I just having a rough week?

This guide breaks down what “getting worse” usually means in CML, the most common warning signs, and the tests doctors rely on to confirm
whether CML is stable, responding, or progressing. (And yesthere’s a section on how to look at your BCR-ABL1 numbers without doom-scrolling
your own bloodwork at 2 a.m.)

Important: This article is for general education and isn’t a substitute for medical advice. If you think something is changing, call your care team.

What “getting worse” means in CML

When clinicians say CML is “worsening,” they usually mean one of these (sometimes overlapping) situations:

• Progression to a more advanced phase (moving from chronic phase toward accelerated or blast phase).
• Loss of response to treatment (for example, labs or molecular tests show the leukemia is no longer being controlled as well as before).
• Resistance or intolerance to a medication (the drug isn’t working as expected, or side effects make it hard to stay on it).

The key idea: doctors don’t define “worse” by a single symptom or one slightly-off lab. They look for trendsand they confirm changes with repeat testing.

Quick refresher: the phases of CML (and why they matter)

CML is often described in three phases based largely on how many immature leukemia cells (“blasts”) are present in the blood or bone marrow,
plus other changes in blood counts and cell behavior.

Chronic phase

This is the most common phase at diagnosis. It often progresses slowly and may cause mild symptomsor none at all.
Treatment tends to work best here.

Accelerated phase

In accelerated phase, the disease biology becomes more aggressive. Blood counts may become harder to control, and symptoms can become more noticeable.
Some guidelines define accelerated phase using blast percentages and other blood findings (like increased basophils or platelet problems).

Blast phase (blast crisis)

Blast phase behaves more like an acute leukemia. It can cause significant symptoms and requires urgent, specialized management.

In plain English: the phase helps your team estimate risk and choose the best next steps. If your CML is in chronic phase and responding well,
the goal is to keep it there.

Symptoms that can signal CML may be worsening

Symptoms alone can’t prove progression, but they can be an early “ping” that something needs checkingespecially if symptoms are new,
persistent, or getting worse over days to weeks.

General “B-symptoms” and energy changes

• Fatigue that’s new or noticeably worse (especially if it’s tied to anemia on labs)
• Fevers without a clear infection
• Night sweats (the kind that may soak pajamas or sheets)
• Unintentional weight loss or reduced appetite

Abdominal fullness or left-sided discomfort

An enlarged spleen (splenomegaly) can cause early fullness after small meals, pressure under the left ribs, or a “tight belly” feeling.
Worsening spleen enlargement can be a clue that CML control is slipping.

Bleeding, bruising, or frequent infections

• Easy bruising, frequent nosebleeds, bleeding gums, or heavier-than-usual bleeding from small cuts
• More infections than usual, or infections that feel harder to kick

Bone pain or new aches that don’t match your usual patterns

Bone pain can happen for a lot of reasons, but in CML it can be associated with higher leukemia activity in the marrow.
If bone pain is new, persistent, or escalating, it’s worth bringing up promptly.

Reality check: CML symptoms can overlap with medication side effects, viral illnesses, stress, low iron, thyroid issues, and about
47 other extremely unhelpful possibilities. That’s why symptoms are a “signal,” not the final verdict.

The real scoreboard: tests that show whether CML control is slipping

If symptoms are the smoke alarm, testing is the fire inspector. Doctors typically use three “levels” of response tracking:
hematologic (blood counts), cytogenetic (chromosome-level), and molecular (BCR-ABL1 levels).

1) Complete blood count (CBC): when the numbers drift

CBC changes that may raise concern include:

• Rising white blood cell count that becomes harder to control
• Worsening anemia (dropping red blood cells/hemoglobin)
• Platelet changeseither very low platelets (thrombocytopenia) or unexpectedly high platelets (thrombocytosis), depending on the situation
• Increasing basophils (a specific white blood cell type that can climb with progression)

Your doctor will also look at the “differential” (the mix of blood cells) and whether immature cells are showing up more than expected.

2) Physical exam and spleen size

A spleen that’s enlarging over timeespecially if it comes with abdominal discomfort or early fullnesscan be a sign the disease is more active.
Sometimes imaging is used, but often clinicians can track meaningful changes through exam and symptom history.

3) Bone marrow testing: blasts and disease behavior

Bone marrow biopsy isn’t needed constantly, but it becomes important when:

• There’s concern about progression to advanced phase
• Blood counts behave unexpectedly
• Molecular response is lost or isn’t being achieved as expected
• Your team needs to evaluate for additional chromosome changes (“clonal evolution”)

4) The BCR-ABL1 PCR test: the most sensitive routine tracker

CML is driven by the BCR-ABL1 fusion gene. Quantitative PCR (often reported on an International Scale) estimates how much BCR-ABL1 is detectable over time.
Think of it like a super-sensitive “leukemia signal strength” meter.

Doctors pay attention to:

• Whether your BCR-ABL1 level is decreasing on schedule after starting or changing therapy
• Whether it plateaus (stops improving)
• Whether it rises (especially if confirmed on repeat testing)

A single rise doesn’t automatically mean the disease is progressing. Labs have natural variation, and short-term issues (missed doses, drug interactions,
a temporary change in absorption) can affect results. What matters most is a confirmed upward trend or loss of a previously achieved milestone.

How doctors decide whether response is “on track” (milestones without the panic)

CML care often uses time-based response goalsespecially early after starting a tyrosine kinase inhibitor (TKI). Milestones help estimate risk and guide
whether to continue the same plan or adjust it.

While exact thresholds can vary by guideline and individual circumstances, common milestone concepts include:

• Early molecular response (a substantial drop in BCR-ABL1 within the first few months)
• Major molecular response (MMR) (a deeper reduction that’s associated with long-term disease control)
• Deep molecular response (even lower detectabilityrelevant for some people considering treatment-free remission later on)

Patterns that can suggest CML control is slipping

• BCR-ABL1 isn’t falling as expected after starting therapy
• BCR-ABL1 rises on repeat testing after being stable or improving
• Loss of a prior response (for example, you had a deep response and now the level is consistently higher)
• Blood counts worsen again after previously normalizing

A practical example: “one weird lab” vs. a real warning

Imagine two scenarios:

• Scenario A: Your BCR-ABL1 was low and stable, then one test comes back a little higher. You also had a stomach bug and missed a few doses.
  Your doctor repeats the test and it returns to baseline. That’s often a “watch and confirm” moment.
• Scenario B: Your BCR-ABL1 rises on two tests in a row, your white count starts climbing, and you’re feeling more left-sided fullness.
  That’s more consistent with a meaningful change that needs action.

In other words: clinicians don’t treat your disease based on a single number. They treat the story the numbers are telling over time.

When “worse” might actually be something else

This matters because it can prevent unnecessary fearand also prevent missed problems that aren’t CML but still need care.

Medication side effects can imitate CML symptoms

TKIs can cause fatigue, muscle cramps, GI symptoms, fluid retention, rashes, and other side effects that may look like “the leukemia is acting up.”
If symptoms change, tell your teamsometimes the fix is supportive care, dose adjustments, timing with food, or a medication switch.

Infections and inflammation can temporarily shift labs

Even a routine viral infection can influence blood counts and how you feel. Your oncologist can help interpret whether a lab shift looks reactive
(your body responding to infection) or leukemia-related.

Adherence and interactions: the unglamorous but powerful variables

Missing doses, taking a TKI inconsistently, or combining it with certain medications or supplements can reduce effectiveness.
If you’re having trouble staying on schedule due to side effects, cost, or routines, tell your teamthis is a fixable problem, and you don’t get a medal
for suffering in silence.

If your doctor suspects CML is worsening, what happens next?

If labs or symptoms raise concern, teams usually take a structured approach. You may see steps like:

Repeat and confirm key tests

• Repeat quantitative PCR to confirm a rise or loss of response
• Repeat CBC and differential to track trends

Evaluate for resistance mutations

If response is lost or inadequate, mutation testing (looking for changes in the ABL1 kinase domain) can help guide which TKI is most likely to work next.

Consider a treatment adjustment

Depending on your situation, your care team may:

• Optimize the current medication (dose/timing/supportive care)
• Switch to a different TKI
• Recommend a clinical trial
• For advanced-phase disease, discuss combinations (TKI + chemotherapy) and whether transplant evaluation is appropriate

The takeaway: “worsening” doesn’t mean “no options.” It usually means “time to re-check the data and choose the next best tool.”

When to call your doctor right away vs. bring it up at the next visit

Always follow your care team’s instructions, but these are common reasons to contact them promptly:

• Fever that doesn’t have an obvious cause, or fever with chills
• New or increasing shortness of breath, chest pain, or severe weakness
• Unusual bleeding (nosebleeds that won’t stop, blood in stool/urine, heavy bleeding)
• Rapidly worsening abdominal pain or severe fullness
• New confusion, severe headache, or concerning neurologic symptoms

If you’re unsure whether something is urgent, it’s reasonable to call and ask. Most oncology teams would rather answer a “maybe” question
than have you wait on a “definitely.”

Questions to ask at your next appointment (bring this list)

• Which phase is my CML currently considered to be in, and what supports that?
• What does my trend in BCR-ABL1 look like over the last 3–12 months?
• Am I meeting the response milestones you expect for my treatment plan?
• If my numbers rose, could anything explain it (illness, missed doses, interactions, lab variation)?
• Do we need to repeat PCR sooner or do additional tests (bone marrow, mutation testing)?
• What symptoms should trigger a call between visits?
• If we change treatment, what’s the goal and how will we measure success?

How caregivers (and future-you) can help spot changes earlier

CML monitoring is partly science and partly pattern recognition. A simple tracking routine can help:

• Keep a symptom note (fatigue level, fevers, night sweats, appetite, abdominal fullness)
• Record lab dates and key results (CBC highlights and BCR-ABL1 %)
• Note disruptions (missed doses, new meds/supplements, GI illness)
• Bring the timeline to appointmentsdoctors love a good timeline

You don’t need a spreadsheet worthy of a NASA launch. A phone note that says “PCR 0.06% → 0.05% → 0.07% (missed 3 doses during flu)” is already helpful.

Experiences: what it can feel like to watch for signs CML is getting worse

Even when CML is medically “well controlled,” the emotional experience can feel like living with a smoke detector that you can’t completely turn off.
Many people describe a cycle: you feel okay, life gets normal, then a lab appointment approaches and suddenly your brain decides it’s auditioning for a
disaster movie narrator.

One common experience is learning the difference between how you feel and how your CML is behaving. Someone might feel exhausted
for a month and assume the leukemia is flaringonly to learn their labs look stable and the real culprits were anemia from another cause, poor sleep,
or medication side effects that can be adjusted. On the flip side, some people feel mostly fine and then discover their PCR trend has changed.
That disconnect is unsettling at first, but it’s also why monitoring works: the tests can catch shifts before symptoms become severe.

Another very real theme is the “numbers relationship.” At the beginning, PCR percentages can feel like a foreign language with decimals that look like they
were invented just to cause stress. Over time, many people find it helps to focus less on a single point and more on the graph in your head:
Is it generally down? stable? rising on repeat? Some patients describe their care team as helping them build “number confidence”understanding which
changes matter, which are just normal lab noise, and when a re-test is the smart move.

People also talk about the practical side: staying consistent with medication in real life. It’s easy to say “take it every day” and much harder to do that
when you’re traveling, dealing with nausea, working long shifts, or simply forgetting because you’re human. Many patients share that the biggest turning point
was not “being perfect,” but being honesttelling the care team when adherence is hard so the plan can be adjusted (pill organizers, phone reminders,
managing side effects, changing dosing time, or switching medications when needed).

Finally, there’s the identity piece: living with a disease that may be managed for years can create a strange mix of gratitude and frustration.
People often describe relief that TKIs can control CML long-term, paired with the emotional weight of long-term monitoring.
Helpful coping strategies that patients frequently mention include having one trusted source of education (instead of Googling everything),
writing down questions as they come up, bringing a friend or family member to important appointments, and setting a simple rule like:
“I’m allowed to worry, but I’m not allowed to worry aloneif something feels off, I message my team.”

If you’re reading this because you’re scared your CML might be changing, you’re not overreactingyou’re paying attention. The most constructive next step
is usually the same: share the symptoms, review the trends, repeat the key tests if needed, and let the data guide the plan. That’s not just medicine;
it’s a way to give your mind something solid to hold onto when uncertainty tries to take the microphone.

Bottom line

CML “getting worse” usually shows up as a combination of symptoms, blood count changes, andmost importantlyconfirmed trends
in molecular testing like BCR-ABL1 PCR. If something feels different, it’s worth a conversation with your oncology team. Often the answer is reassurance.
Sometimes the answer is “let’s adjust the plan.” Either way, paying attention early is a strength, not a problem.